NEW YORK (TheStreet) -- Catabasis Pharmaceuticals (CATB) - Get Report shares are climbing 0.92% to $13.12 in after-hours trading on Thursday after the company gained 8.33% to $13 in intraday trading following its initial public offering.

The Cambridge, MA-based clinical stage biopharmaceutical company priced its upsized sale of 5 million shares at $12 per share.

Catabasis, a company that develops technology for improving drug efficacy, priced its IPO below analysts' $13 to $15 expectations.

Image placeholder title

CATB Price

data by

YCharts